A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic
Investigator(s):
Bartosz Chmielowski, M.D.;
Organization:
UCLA
NCT Number:
Disease Name:
Solid Tumor
Disease Category:
Trial Phases:
Phase 1
Trial Status:
Recruiting
Trial Contact:
Louis A. Sloniker
(310) 794-6993
LSloniker@mednet.ucla.edu